Breast Cancer in Senior Patients: Role of Comprehensive Geriatrics Assessment and Comorbidities

Marco Ruiz*, Charles Cefalu and Tom Reske
Department of Medicine, Section of Infectious Disease, Louisiana State University, USA

Abstract

Background: Breast cancer is the most common cancer in women in the United States and Europe. Comprehensive geriatrics assessment (CGA) is a key tool for geriatricians and accomplishes appropriate stratification of senior patients into independent and frail patients. CGA involves a thorough assessment of different domains including psychical and psychological spheres (functional assessment, cognitive, depression, nutrition status, social functioning). Some reviews have explored the use of CGA in elderly breast cancer patients but more studies comparing the CGA and abbreviated versions in elderly breast cancer patients are needed.

Methods: We searched PubMed, restricted to the past 10 years, with the terms “breast cancer”, “elderly patients”, “older patients and breast cancer”, “Comprehensive geriatrics assessment”, “frail breast cancer patients”, “comorbidities and breast cancer,” and “geriatric syndromes”.

Discussion: CGA may detect multiple problems in senior cancer patients. Moreover, CGA is an excellent tool to stratify patients into healthy independent and frail patients. It gives an insight on first line treatment and adjuvant chemotherapy options in this population. Despite its benefits issues such as lack of time, length of the test, difficulty to interpret results and need for regular follow up, prevent its use in busy oncology practices. Shorter versions of the CGA have been tried but these tools face problems with generalizability and validity. Comorbidities, frailty status, and the presence of geriatric syndromes have been directly related to increased morbidity and mortality in elderly breast cancer patients.

Conclusion: Breast cancer prevalence continues to increase specially in senior patients. Comprehensive geriatrics assessment has been advocated as a screening and follow up tool for senior patients. In senior breast cancer patients, CGA may help stratify patients who may develop adverse reactions to treatment strategies. The roles of comorbidities, geriatric syndromes, and frailty status and their impact on survival need to be elucidated.

Introduction

Breast cancer is the most common cancer in women in the United States and Europe. Aging is a very important risk factor for developing breast cancer. With aging of population it is expected that the prevalence of breast cancer will increase in the incoming years in the senior population (>65 years). In fact, it is expected that by the year 2035, 60% of new patients are 70 years or older [1]. Therefore a thorough evaluation of elderly breast cancer patients is be needed to properly stratify this population into those who may respond adequately to treatment strategies and others who may present with complications associated with treatment [1-5].

Comprehensive geriatrics assessment (CGA) is a key tool for geriatricians [1-4]. It involves a thorough assessment of different domains including psychical and psychological spheres (functional assessment, cognitive, depression, nutrition status, social functioning [6]. It has been used with success in geriatric practice for evaluation of senior patients by stratifying patients based in functional status (independent, partially dependent, and fully dependent). A recent meta-analysis study has showed that when CGA is used mortality of acutely hospitalized elderly patients decreases at 1 year after discharge [6].

The applicability of comprehensive geriatrics assessment in other medical specialties has been suggested with success in certain occasions but with some obstacles in other cases [3,4,7-9]. In oncology practice the value of comprehensive geriatrics assessment has been reviewed by many authors who do agree of the need to incorporate the comprehensive geriatrics assessment into oncology practice [1-3,5,7-9].

Many obstacles such as lack of time, lengthy test, difficulty to interpret results and need for follow regular follow up; have been identified when trying to incorporate CGA in clinical oncology practice [1-3,7,10,11]. Some attempts to shorten the CGA were reviewed and published in the literature. These shorter versions face issues related to generalizability, reliability, and validity [3,4,10,11].

Even though the use of CGA is highly recommended for senior cancer patients, it is not widely used in oncology practice. Assessment of senior patients in general is performed with other oncology-based tools such as the ECOG and the Karnofsky index and performance status [7]. These tools partially determine functional ability of senior patients but important aspects of geriatrics assessment such as cognitive function, social functioning, nutritional status, presence of depression, and medication interactions are missed [4,6,12].

References


Copyright: © 2011 Ruiz M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Appropriate stratification of senior patients into independent, partially dependent, and fully dependent or frail groups is crucial for determining correct medical interventions [5]. It has been shown that highly functional patients usually respond well to chemotherapy/radiation/surgery interventions while on the other hand frail patients present with multiple complications as a result [3,4].

This paper reviews the role of comprehensive geriatrics assessment in the initial evaluation and subsequent follow up of elderly breast cancer patients, the role of comorbidities and geriatric syndromes in elderly breast cancer outcomes and survival.

Breast cancer management in senior patients

Current recommendations advocate an individualized screening in senior patients based on functional status and estimated life expectancy [1,2,13,14]. The American Geriatrics Society recommends annual screening mammography up to the age of 85, if their life expectancy is at least 4 years.

The role of diagnostic mammograms have been discussed in the literature [1,2]. Studies have suggested that senior breast cancer patients should be treated based on functional status, comorbidities and prognostic factors and not just based on chronological age [2,3]. In addition to the standard of care, mammogram, and ultrasound, MRI screening of contralateral breast in newly diagnosed breast cancer patients showed benefits even in senior patients [10].

Surgery is the mainstay of treatment for senior patients. It has been associated with lower morbidity and longer survival in octogenarians [11]. Interestingly, recent data suggest that women> 70 were more likely to receive no surgical treatment and undergo mastectomy in some cases [15,16]. There is some controversy about the utility of lymph node dissection in senior patients [16,17].

Adjuvant therapy has also been advocated for senior patients. An adjuvant US trial published in 2005 showed that women age 65 or older had an increased overall survival and relapse free survival using standard of care combination chemotherapy versus the single agent capecitabine. This trial confirmed an improved outcome with combination chemotherapy compared to a single agent regimen in the adjuvant setting as it is seen in younger breast cancer patients [18]. Sautler et al. [19] suggest that based on risk stratification, independent senior patients should be given chemotherapy, and radiotherapy as standard adjuvant chemotherapy. Transcutaneous is thereby recommended as adjunct to standard chemotherapy in HER 2 positive disease. Retrospective studies from France confirmed efficacy and safety of standard docetaxel and cyclophosphamide in 110 seniors (>70 years) [20]. Kimmick [21] and Garg et al. [22] found similar response and tolerability to standard chemotherapy regimens.

Adjuvant hormonal therapy has been used successfully in adjuvant setting in hormone receptor positive disease. Beside tamoxifen, aromatase inhibitors have been proven to be well tolerated. The inhibitors are frequently used in elderly patients, although long term data on use in the elderly is not as extensive compared to tamoxifen [23]. It remains important to screen for bone health prior to start of an aromatase inhibitor, as bone density can significantly decline during therapy. Start of bisphosphonate therapy with calcium and vitamin D is recommended if a decline in bone density is diagnosed.

Radiation therapy in the adjuvant setting is also commonly used to prevent local recurrence. Radiation is usually well tolerated. A study by Hughes et al. [24] in patients > 70 years in early stage disease questioned though the benefit from radiation therapy in this subset of patients. Radiation was shown to prevent local recurrence compared to observation 1 versus 4%, there was no benefit in overall survival.

Targeted therapies for certain breast tumors (HER 2 positive) have been reviewed in the literature. These therapies may significantly allow longer disease-free survival times. These drugs are not free of side effects and in fact may cause significant issues in elderly patients (cardiotoxicity, deep vein thrombosis, gastrointestinal and dermatologic). New trials including senior patients are urgently needed to clarify the potential benefits of this group of agents [25].

In summary, clinical trials have not included a good number of elderly breast cancer patients (>70) [3,4] Screening for elderly (>70 years) patients is recommended based on individual patient characteristics. Even though surgery is the mainstay of treatment it appears that surgical options are not offered as frequently as other treatment modalities in this population. Adjuvant therapy and aromatase inhibitors appear to be safe in the independent/functional subset of elderly patients. Targeted therapies need to be further investigated in elderly breast cancer patients.

Comprehensive geriatrics assessment as a tool for a thorough stratification of senior breast cancer patients

The role and benefits of comprehensive geriatrics assessment has been discussed widely in the literature [8,26-29], CGA may detect multiple problems in elderly cancer patients [27]. Moreover, CGA is an excellent tool to stratify patients into healthy independent and frail patients [9]. CGA has also been used as a very precise prognostic tool in oncology settings [30,31]. In fact this tool helps to adapt cancer treatment for these patients [32].

In busy oncology settings the majority of oncologists use the ECOG (Eastern Cooperative Oncology Group) evaluation tool to stratify (functional and non-functional) patients. Multiple authors have compared CGA and ECOG (Eastern cooperative Oncology Group) evaluation tools and have shown that CGA is a more thorough tool able to detect issues not detected by ECOG [3,4]. Therefore, the CGA seems to be the best tool available for evaluation of elderly cancer patients. Unfortunately issues such as the length of the CGA, busy oncology practices, lack of trained staff prevents its use in oncology practice. As a result of this shorter version of the CGA has been suggested.

The role of shorter versions of the CGA has been reviewed in the literature. Aparicio et al. [32], piloted a study of 21 patients over the age of 70 using a mini-geriatrics assessment tool (shorter version of CGA). The aim of the study was to evaluate feasibility of a mini geriatrics assessment to adapt the anticancer therapy. These authors concluded that the mini CGA lead an adaptation of the non-oncology treatment in 72% of cases and of the social care in 38% but the oncology strategy was never modified [32]. In a retrospective analysis, Overcash et al. [33] reviewed over 500 charts in patients over 70 year with the intent to validate an abbreviated version of CGA (15 items ). The study showed a direct correlation between the abbreviated form and the entire CGA. The researchers recommended the abbreviated form as a screening tool for those seniors who would benefit from the entire CGA.

Another shorter version a brief comprehensive self-administered questionnaire (functional status, comorbidity, psychological status, nutritional status, and social support) was conducted in 250 patients in an academic oncology practice. The median time to complete the questionnaire was 15 minutes. Information collected helped to identify
In summary, the CGA has a pivotal role in the evaluation of elderly breast cancer patients. The lack of clinical trials where the CGA is included has prevented its dissemination into oncology practice. More studies comparing the CGA and abbreviated versions in elderly breast cancer patients are needed.

Role of comorbidities and geriatric syndromes

The interrelation among comorbidities, geriatric syndromes, aging, frailty, chronic inflammation and cancer has been reviewed in some reports. Siegelmann-Danieli et al. [40] revised these associations among 992 elderly breast cancer patients. Interestingly, these authors found that the presence of comorbidities may adversely affect breast cancer survival. This association seems to be stage dependent major negative impact of comorbidities on early breast cancer stages. These authors suggested a stage shift with patients with more comorbidities having similar outcomes compared to patients with advanced breast cancer stages.

The association of geriatric syndromes and cancer was reviewed by Mohile et al. [41]. In a study of Medicare beneficiaries there was an association between the diagnosis of geriatric syndromes and cancer [41]. Patient with 1 or more geriatric syndromes had worse outcomes in terms of adverse reactions and mortality than patients without geriatric syndromes. Other authors explained these findings by looking into the association of geriatric syndromes and frailty status [7,42].

Comorbidities have been directly related to increased morbidity and mortality in senior cancer patients. In a study of 64,034 patients with a median age of 75 years, a total of 13 comorbidities were found to be related to increased morbidity and mortality. The presence of any of these comorbidities negatively affected survival independent of breast cancer stage and type of tumor [43]. In another study of 159 senior breast cancer patients, more than 65% had comorbidities the most common being cardiovascular conditions (coronary artery disease and hypertension, and transient ischemic attack) [1].

In another study Girones et al. [44] showed that senior breast cancer patients suffer from more comorbidities on follow up after initial early breast cancer diagnosis. Ninety one patients with an average age of 76 years at time of surgery for breast cancer were identified. The median follow up was 5 years. The study showed that the subgroup of functional patients continued with follow up more frequently than frail patients. Comorbidity was independent of functionality and age [44].

There seems to be a direct correlation among comorbidities, geriatric syndromes and outcomes in senior breast cancer patients. Some authors suggest the possibility of a stage shift on patients with multiple comorbidities whose adverse events and mortality outcomes seem to be similar that those of patients with more advanced breast cancer stages. Similarly, the presence of one or more geriatric syndromes is related to adverse outcomes. The ability to screen and diagnose these issues is of paramount importance for patient stratification. CGA appears to be a critical tool to achieve appropriate and thorough patient evaluation.

Frail breast cancer patients

Senior breast cancer patients who are frail (as defined by frailty scores) are subject to multiple complications. The presence of geriatric syndromes (falls, incontinence, dementia, depression, nutritional problems) also predisposes senior breast cancer patients to vulnerability and increased mortality outcomes [45,46].

Treatment modalities have not been established for senior frail
breast cancer patients. In the majority of cases, palliative options are offered but decisions take into consideration possible adverse reactions and side effects as opposed to quality of life [47].

Primary endocrine therapy has been suggested for frail breast cancer patients [16]. Single agents are preferred regimens for this population. The specifics of dosing and dose reductions for these patients are still to be determined [45-50]. Generally, management of frail senior breast cancer patients has not been studied in depth. Further it is hypothesized that the frail nature of these patients may cause multiple adverse reactions, complications and adverse outcomes.

Conclusions

Breast cancer prevalence continues to increase specially in senior patients. It is expected that by the year 2030, 60% of patients will be >70 years of age. The Comprehensive Geriatrics Assessment has been advocated as a screening and follow up tool for senior patients. In senior breast cancer patients, CGA may help stratify patients who may develop adverse reactions to treatment strategies. The roles of comorbidities, geriatric syndromes, and frailty status and their impact on survival need to be elucidated.

Frail senior breast cancer patients represent a unique population. Treatment strategies and issues related to quality of life also need to be addressed. The inclusion of frail senior breast cancer patients in future studies is of paramount importance to outline strategies are needed to better care this population.

Finally, the CGA is and will continue to be the gold standard for evaluation of elderly breast cancer patients. Even though shorter versions have been revised issues related to generalizability and validity are common to these tools. The CGA should be included in clinical trials and comparisons between the CGA, and shorter or abbreviated forms are needed for further management of elderly breast cancer patients.

References


